Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 664 results for kidney or kidneys or renal

  1. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  2. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  3. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

  4. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  5. Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery

    New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.

  6. Biggest shake-up in type 2 diabetes care in a decade announced

    Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.

  7. Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes

    Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.

  8. Hypertension case finding and optimal management and lipid optimal management

    CVD, and includes guidance for people who also have diabetes or chronic kidney disease. Show NICE quality standards Hypertension in...

  9. Taking a proportionate approach to technology appraisals

    Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.

  10. Diabetes

    Diabetes is one of the key clinical areas of health inequalities identified in NHS England’s Core20PLUS5 framework for children and young people.

  11. 'Artificial pancreas' transforming the lives of thousands of children and young people with type 1 diabetes

    The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.

  12. Key question: caring

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  13. NICE leads the way in approving breakthrough treatment for multiple myeloma

    People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.

  14. Cost saving guidance

    with acute or chronic severe sciatica. Cash savings: £2,000 Guideline on renal and ureteric stones: assessment and management (NG118)...

  15. Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease

    New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.